You are here

  • Home
  • Archive
  • Volume 79, Issue 10
  • Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Citation Tools

Article menu

Download PDFPDF

XML
Autoinflammatory disorders
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ozen S, Ben-Cherit E, Foeldvari I, et al
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
Annals of the Rheumatic Diseases 2020;79:1362-1369.